Altimmune's Participation in Key Investor Conferences
GAITHERSBURG, Md. — Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company focused on developing advanced therapeutics for liver and cardiometabolic issues, has recently shared exciting news with investors. Members of the management team will engage with investors at notable upcoming conferences, presenting an excellent opportunity for stakeholders to connect and learn more about the company's innovative approaches.
Conference Details
Stifel 2025 Healthcare Conference
Scheduled for Wednesday, November 12, 2025, Altimmune will host a fireside chat at 10:00 a.m. ET. This session promises to provide valuable insights into the company’s strategic initiatives and advances in treatment options.
Jefferies Global Healthcare Conference
On Thursday, November 20, 2025, Altimmune will participate in another significant event, with a fireside chat arranged for 9:30 a.m. GMT. Both sessions highlight the company's commitment to transparency and investor engagement.
Webcast Availability
For those interested in following along, the sessions will be available via webcast. Viewers can find the links on the Events section of the Altimmune website, ensuring that anyone interested in the developments can access the discussions live.
About Altimmune
Altimmune has made significant strides as a clinical-stage biopharmaceutical firm, focusing on groundbreaking peptide-based therapies that target liver-related and cardiometabolic diseases. Their lead candidate, pemvidutide, is a dual receptor agonist that holds promise for treating metabolic dysfunction-associated steatohepatitis (MASH), among other conditions.
In an era where metabolic disorders are on the rise, the work of Altimmune is particularly crucial. Their focus on addressing conditions like alcohol use disorder and alcohol-associated liver disease positions them as innovators in a challenging healthcare landscape.
Investor Engagement and Outlook
Altimmune's proactive approach to investor relations is commendable. By participating in key conferences, they are not just sharing their journey but actively involving their stakeholders in the conversation about future growth and development. The company's transparency and willingness to engage with investors signal a promising path ahead.
Keeping an eye on the developments from these conferences will be valuable for investors looking to understand more about the company’s future. The discussions are expected to cover not only the current state of their projects but also the long-term vision that drives Altimmune's innovations.
Engaging with Altimmune
Staying connected with Altimmune is essential for investors enthusiastic about the ever-evolving pharmaceutical landscape. The company encourages stakeholders to follow them on social media platforms, including LinkedIn and X, for the latest updates and insights into their ongoing projects.
Frequently Asked Questions
What conferences will Altimmune be attending?
Altimmune will attend the Stifel 2025 Healthcare Conference and the Jefferies Global Healthcare Conference.
When is the Stifel 2025 Healthcare Conference?
The Stifel 2025 Healthcare Conference is scheduled for November 12, 2025.
What is pemvidutide?
Pemvidutide is Altimmune's lead product candidate designed to treat liver diseases, including metabolic dysfunction-associated steatohepatitis.
How can I follow Altimmune's updates?
You can follow Altimmune on LinkedIn and X for the latest news and updates on their developments.
How does Altimmune engage with investors?
Altimmune actively participates in investor conferences and hosts webcasts to engage with stakeholders and share insights about their progress and future plans.
